
A novel method was developed and validated for assessing the efficacy of Bevacizumab (Bev) in Recurrent Respiratory Papillomatosis (RRP) using ImageJ software to calculate standardized lesion volumes from laryngoscopic images. This approach was compared to the Derkay score. Twenty-one RRP patients received a three-dose Bev induction therapy followed by surgical intervention. The response rate improved from 75% after the first treatment to 100% after the third. Recurrence occurred in 76% of surgically treated patients, with a mean recurrence time of 114.23 days, and most lesions were smaller than baseline. Adverse reactions, including transient hypertension, were manageable.
Like
Save
Share